Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BI 685509 in Healthy Chinese and Japanese Volunteers
NCT03259464Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2017
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, single-blind trial in diabetic kidney disease (DKD), chronic kidney disease (CKD), systemic sclerosis (SSc) and 1 more comparing BI 685509 with Placebo (2 arms). Primary endpoint: Number of subjects with drug-related Adverse Events. Started Sep 2017; status: completed.
02
Drugs
avenciguat
03
Conditions
diabetic kidney disease (DKD)chronic kidney disease (CKD)systemic sclerosis (SSc)Portal Hypertension (PH)
Beyond the preview
Go deeper on NCT03259464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03259464.